Daiichi Sankyo has picked up an exclusive license to develop and commercialise AstraZeneca’s influenza vaccine Flumist Quadrivalent in Japan.
The nasal spray is a live attenuated vaccine containing four protective strains, and is currently being prepared for regulatory submission in the country.
The deal gives Daiichi full responsibility for future development and commercialisation of the vaccine in its domestic market and ownership of the marketing authorisation if approved.
Financial specifics were not revealed, but the firms did say that Daiichi will pay AZ an upfront fee with subsequent development milestones and sales-related payments post launch.
Flumist Quadrivalent was approved in the US in early 2012.